Oxford Biodynamics Plc:医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Oxford Biodynamics Plc - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C10447
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neurodegenerative conditions. Its biomarker discovery platform is used for the detection of aberrant gene expression. The company’s products are used in the areas of breast cancer diagnostics, hepatocellular carcinoma diagnostics, nasopharyngeal carcinoma diagnostics, prostate cancer progression, melanoma diagnostics, and age related disease diagnostics. Oxford Bio is headquartered in Oxford, Oxfordshire, the UK.

Oxford Biodynamics Plc – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Oxford Biodynamics Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Oxford Biodynamics Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Oxford Biodynamics Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Oxford Biodynamics Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Oxford Biodynamics Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Oxford Biodynamics Plc, Medical Equipment, Deal Details 11
Private Equity 11
GL Capital Invests USD12.5 Million in Oxford BioDynamics 11
Partnerships 13
Nova Satra Enters into Licensing Agreement with Oxford BioDynamics 13
Oxford BioDynamics Enters into Agreement with Casa Sollievo della Sofferenza 14
Oxford Biodynamics Enters into Agreement with Holos Life Sciences 15
Oxford Biodynamics Enters Into Agreement With University of Glasgow For Epigenetic Biomarkers 16
Equity Offering 17
Oxford BioDynamics Raises USD24.9 Million in Issue of New Ordinary Shares 17
Oxford Biodynamics Plc – Key Competitors 18
Oxford Biodynamics Plc – Key Employees 19
Oxford Biodynamics Plc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Strategy And Business Planning 21
Nov 12, 2018: Oxford BioDynamics forms new alliance to identify autism biomarkers 21
Financial Announcements 22
May 22, 2018: Oxford Biodynamics: Interim Results For The Six-Month Period Ended 31 March 2018 22
Jun 13, 2017: Oxford Biodynamics Interim Results For The Six-Month Period Ended 31 March 2017 23
Jan 31, 2017: Oxford BioDynamics Announces Final Results for the Year Ended 30 September 2016 28
Corporate Communications 30
Sep 15, 2017: Oxford BioDynamics appoints Paul Stockdale as Chief Financial Officer and Executive Director on the Board 30
Jun 30, 2017: Oxford BioDynamics: Appointment of Paul Stockdale as Chief Financial Officer 31
Mar 09, 2017: Oxford BioDynamics announces appointment of Martin Reeves as Senior Vice President of Commercial Development 32
Feb 13, 2017: Oxford BioDynamics appoints Dr Claudio Carini as an Advisor 33
Product News 34
Jul 19, 2018: Oxford BioDynamics announces grant of Canadian patent for its proprietary technology platform, EpiSwitch 34
Feb 14, 2018: Oxford BioDynamics announces grant of Indian patent for its proprietary technology platform, EpiSwitch 35
Nov 15, 2017: Oxford BioDynamics presents latest immunotherapy data at the NIH Biomarker Consortium Cancer Steering Committee Annual Symposium, in Washington, DC 36
Oct 13, 2017: Oxford BioDynamics presents at the Diabetes Asia 2017 Conference 37
Oct 11, 2017: Oxford BioDynamics presents ALS signatures at NEALS 38
Oct 03, 2017: Oxford BioDynamics announces grant of US patent for its proprietary technology platform, EpiSwitch 39
May 31, 2017: Nature (Scientific Reports) publication highlights advantages of EpiSwitch technology platform 40
Other Significant Developments 41
May 23, 2017: Oxford BioDynamics enters into development agreement with two top 10 global pharmaceutical companies 41
Jan 23, 2017: Oxford BioDynamics enters into pilot project with EpiFit to analyse the effect of fitness regimes using EpiSwitch 42
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Oxford Biodynamics Plc, Medical Equipment, Key Facts 2
Oxford Biodynamics Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Oxford Biodynamics Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Oxford Biodynamics Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Oxford Biodynamics Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Oxford Biodynamics Plc, Deals By Market, 2012 to YTD 2018 9
Oxford Biodynamics Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
GL Capital Invests USD12.5 Million in Oxford BioDynamics 11
Nova Satra Enters into Licensing Agreement with Oxford BioDynamics 13
Oxford BioDynamics Enters into Agreement with Casa Sollievo della Sofferenza 14
Oxford Biodynamics Enters into Agreement with Holos Life Sciences 15
Oxford Biodynamics Enters Into Agreement With University of Glasgow For Epigenetic Biomarkers 16
Oxford BioDynamics Raises USD24.9 Million in Issue of New Ordinary Shares 17
Oxford Biodynamics Plc, Key Competitors 18
Oxford Biodynamics Plc, Key Employees 19
Oxford Biodynamics Plc, Other Locations 20

List of Figures
Oxford Biodynamics Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Oxford Biodynamics Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Oxford Biodynamics Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Oxford Biodynamics Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Oxford Biodynamics Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Oxford Biodynamics Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Oxford Biodynamics Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Oxford Biodynamics Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Oxford Biodynamics Plc:医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CompuGroup Medical Deutschland AG (COP):医療機器:M&Aディール及び事業提携情報
    Summary CompuGroup Medical Deutschland AG (CGM) is a provider of medical software products and healthcare services. The company provides products such as communication solutions, software assisted medicine, dentist information systems, ambulatory information systems, drug safety and patient marketin …
  • InVitae Corp (NVTA):製薬・医療:M&Aディール及び事業提携情報
    Summary Invitae Corp (Invitae), formerly Locus Development Inc, is a genetic information company which processes DNA-containing samples, analyzes information about patient-specific genetic variation and generates test reports for clinicians and their patients. The company’s portfolio of diagnostic t …
  • Seagate Technology Public Limited Company (STX):企業の財務・戦略的SWOT分析
    Seagate Technology Public Limited Company (STX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Guararapes Confeccoes SA:企業の戦略・SWOT・財務情報
    Guararapes Confeccoes SA - Strategy, SWOT and Corporate Finance Report Summary Guararapes Confeccoes SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Akenerji Elektrik Uretim AS (AKENR):企業の財務・戦略的SWOT分析
    Akenerji Elektrik Uretim AS (AKENR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Novozymes AS (NZYM B):製薬・医療:M&Aディール及び事業提携情報
    Summary Novozymes AS (Novozymes) is a biotech company that produces, markets and sells a range of industrial enzymes and microorganisms. The company provides enzymes for detergents, technical, food and feed industries. It supplies a range of microorganisms for use in agriculture, industrial cleaning …
  • BP Australia Group Pty Ltd:企業の戦略的SWOT分析
    BP Australia Group Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • BKW AG:企業の戦略・SWOT・財務分析
    BKW AG - Strategy, SWOT and Corporate Finance Report Summary BKW AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • PPL Corp:企業の発電所・SWOT分析2018
    PPL Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executive …
  • Shenzhen Salubris Pharmaceuticals Co Ltd (002294):製薬・医療:M&Aディール及び事業提携情報
    Summary Shenzhen Salubris Pharmaceuticals Co Ltd (Salubris) is a pharmaceutical company that research, develops, manufactures and distributes pharmaceutical and healthcare products. The company produces tablet, capsule, and injection formulations and active pharmaceutical ingredients, among others. …
  • Neurolixis Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Neurolixis Inc (Neurolixis) is an early-stage biopharmaceutical company that discovers and develops novel drugs for the treatment of human central nervous system disorders. The company’s pipeline product portfolio includes NLX-112, a drug candidate intended for the treatment of L-DOPA-induce …
  • Gold Fields Limited:企業のM&A・事業提携・投資動向
    Gold Fields Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gold Fields Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Celsia SA ESP (CELSIA):電力:M&Aディール及び事業提携情報
    Summary Celsia SA ESP (Celsia), formerly Compania Colombiana de Inversiones SA ESP, a subsidiary of Grupo Argos SA, is an energy company that generates, transmits, distributes, and sells electricity. The company’s product categories include home line, solar energy, backup energy, thermal network, ef …
  • Currence Holding B.V.:企業の戦略・SWOT・財務情報
    Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report Summary Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • World Of Medicine GmbH:企業の戦略的SWOT分析
    World Of Medicine GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Tokyo Electric Power Company Holdings Inc (9501):企業の財務・戦略的SWOT分析
    Tokyo Electric Power Company Holdings Inc (9501) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Regenicin Inc (RGIN):医療機器:M&Aディール及び事業提携情報
    Summary Regenicin Inc (Regenicin), formerly Windstar Inc is a biotechnology company that develops regenerative cell therapies. The company offers NovaDerm, a tissue-engineered skin prepared from autologous skin cells. Its NovaDerm technology uses the patient’s own skin cells to generate living, tiss …
  • Napp Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Napp Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • New York Blood Center:製薬・医療:M&Aディール及び事業提携情報
    Summary New York Blood Center (NYBC) is a non-profit healthcare organization that offers blood collection and distribution. The organization's blood products comprise red blood cells, plasma products, platelets, frozen blood and washed products, whole blood and granulocytes. It offers medical servic …
  • Lietuvos Energija UAB:電力:M&Aディール及び事業提携情報
    Summary Lietuvos Energija UAB (Lietuvos Energija) is a state-owned utility. The utility’s activities include power and heat distribution and supply; natural gas trade and distribution; construction and maintenance of power plants and grid; development of energy infrastructure and green energy; and d …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆